Background: The incidence of obesity is increasing dramatically to epidemic proportions. There are few approved anti-obesity pharmacological treatments and their modest efficacy and safety concern. Presently two drugs approved by US FDA for treatment of obesity are Phentermine and Orlistat. Objective: The aim of this review is to discuss the new pharmacological agents that are under development and that may be eventually used for treatment of obesity. Low doses of topiramate and phentermine: The rational for combining topiramate with phentermine is to minimise the required dose of each of the medication thereby opening up more than one pathway to satiety in hope of achieving great efficacy. Bupropion and Naltriaxone: Monotherapy with bupropion shown weight loss of 2.8 kg at 52 weeks and this does not meet FDA criteria for an antiobesity drug. Naltriaxone alone is associated with minimal weight loss. Combination would be associated with weight reduction. Zonisamide and Bupropion: Zonisamide induces weight loss as a side effect. It was thought that bupropion when added to zonisamide decreases the depressive and sedative properties associated with zonisamide while the latter might reduce the likelihood of bupropion-induced seizures. Liraglutide: Victoza (liraglutide) is a once-daily version of the new-generation GLP-1(glucagon like peptide) analogs. Victoza reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake. Cetilistat: an inhibitor of pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. This drug is similar to the currently FDA-approved drug orlistat. Phase III trials of cetilistat are currently under way in Japan. TTP 435:TTP435 is a potent and selective inhibitor of AgRP. TTP435 was shown to reduce food intake and body weight gain, reduce fat composition, and reduce insulin levels in a dose-dependent fashion. __ampersandsignnbsp;GSK 598809: GSK 598809 is a D3 antagonist that blocks dopamine. It is thought that blocking dopamine may reduce the intake of foods high in fat and sugar. Conclusion: Many factors have mitigated against active drug development, including the poor safety and efficacy of previous antiobesity drugs. The new generation of antiobesity drugs offers hope for the management of obesity, although no single agent is likely to be a solution.